Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryo Morita

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Journal of Cachexia, Sarcopenia and Muscle|October 1, 2024
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050AKeita Miura, Takehito Shukuya, Naoki Furuya, et al.
Clinical Lung Cancer|November 19, 2023
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q)Shinji Nakamichi, Kaoru Kubota, Kotone Matsuyama, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, et al.
Cancer Medicine|July 20, 2024
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysisYasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, et al.
Cancer Science|January 30, 2024
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, et al.
ESMO Open|July 22, 2020
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)Kyoichi Okishio, Ryo Morita, Junichi Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 16, 2019
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in JapanRyo Morita, Kyoichi Okishio, Junichi Shimizu, et al.
The Lancet. Respiratory Medicine|August 19, 2024
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trialYoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Journal of Cachexia, Sarcopenia and Muscle|October 1, 2024
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050AKeita Miura, Takehito Shukuya, Naoki Furuya, et al.
Clinical Lung Cancer|November 19, 2023
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q)Shinji Nakamichi, Kaoru Kubota, Kotone Matsuyama, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, et al.
Cancer Medicine|July 20, 2024
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysisYasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, et al.
Cancer Science|January 30, 2024
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, et al.
ESMO Open|July 22, 2020
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)Kyoichi Okishio, Ryo Morita, Junichi Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 16, 2019
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in JapanRyo Morita, Kyoichi Okishio, Junichi Shimizu, et al.
The Lancet. Respiratory Medicine|August 19, 2024
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trialYoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, et al.
Pageof 10